Clinical Trials Directory

Trials / Completed

CompletedNCT06798285

Comparision of Retinal Function and Macular Structure After 27G Pars Plana Vitrectomy With Minimal Illuminiation

Comparision of Retinal Function and Macular Structure After 27G Pars Plana Vitrectomy With Minimal Heads-up Versus Standard Illuminiation in Patients With Idiopthic Epiretinal Membranes

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Pomeranian Medical University Szczecin · Academic / Other
Sex
All
Age
60 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Purpose: To analyze the clinical benefits of using the NGENUITY 3D Visualization System in vitreoretinal surgery with low levels of endo-illumination, focusing on functional and structural retinal protection in patients with idiopathic epiretinal membranes (ERM). Design: Prospective, randomized, comparative study. Methods: Forty pseudophakic patients (29♀, 11♂; age 60-80 years) with ERM underwent 27G pars plana vitrectomy (PPV) and were randomly divided into two groups: Group I (20 eyes, stand-ard microscope \[Hi-R 900\], endo-illumination 3.2 Lm) and Group II (20 eyes, 3D heads-up NGE-NUITY system, endo-illumination 0.5 Lm). Preoperative and 6-month postoperative evaluations included slit-lamp examination, intraocular pressure (IOP, Pascal tonometer), Distance Best Correct-ed Visual Acuity (DBCVA, logMAR), Central Subfield Thickness (CST), Retinal Nerve Fiber Layer Thickness (RNFL, OCT), Pattern ERG (PERG), multifocal ERG (mfERG), flash ERG (ERG, IS-CEV standards), and retinal sensitivity (HFA macula test). Surgery time, xenon light exposure, ERM/ILM peeling time, fundus autofluorescence (FAF), metamorphopsia incidence, and intra-/postoperative adverse events were analyzed. Results were statistically evaluated (p \< 0.05).

Conditions

Interventions

TypeNameDescription
PROCEDUREPars Plana Vitrectomy StandardGroup I: PPV with endoillumination set at 3.2 Lm.
PROCEDUREPars Plana Vitrectomy 3DGroup II: PPV with endoillumination set at 0.5 Lm.

Timeline

Start date
2021-02-18
Primary completion
2024-06-28
Completion
2024-06-28
First posted
2025-01-29
Last updated
2025-01-29

Locations

1 site across 1 country: Poland

Source: ClinicalTrials.gov record NCT06798285. Inclusion in this directory is not an endorsement.